Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of theophylline in treating patients who have in situ, stage I, or stage II chronic lymphocytic leukemia.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Phase II Study of Theophylline in Chronic Lymphocytic Leukemia|
|Study Start Date:||May 1999|
|Primary Completion Date:||September 2002 (Final data collection date for primary outcome measure)|
OBJECTIVES: I. Determine the response rate in asymptomatic patients with stage 0, I, or II B-cell chronic lymphocytic leukemia treated with theophylline. II. Determine the toxicity of this treatment in these patients.
OUTLINE: Patients receive oral theophylline daily. Daily treatment continues for a maximum of 6 months in the absence of disease progression or unacceptable toxicity. Patients are followed every 4 months for 1 year.
PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study over approximately 10 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00003808
Show 71 Study Locations
|Study Chair:||Della Makower, MD||Albert Einstein College of Medicine of Yeshiva University|
|Study Chair:||Rajiv K. Pruthi, MBBS||Mayo Clinic|